Comments
Medicamen Biotech on Monday entered into an agreement for acquisition of the entire equity share capital of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia), from its existing shareholders for a consideration aggregating to A$420,000.
Subsequently, on Tuesday, it entered into an agreement to sell 25 per cent equity share capital of OPAL held by the company to Baxyran Healthcare Private Limited for ₹51.53 lakh. Post the transfer, OPAL would cease to be the company’s wholly-owned subsidiary, it said in a notice to the exchanges.
Shares of BSE-listed Medicamen closed 1.17 per cent lower at ₹358.60.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.